Under the 10-year deal, SomaLogic will analyze at least 250,000 clinical samples to support Novartis' drug development work and its own test development.
Within the program, Ochsner is hoping to improve preventive care in certain cancer and cardiac conditions with information from genetic tests performed by Color.
The companies will combine clinical genetic testing services with data management technology to support precision medicine for rare diseases.
WUSTL spinout PercayAI will provide augmented intelligence technology to Canopy Biosciences' RNA-seq and NanoString tests to inform drug discovery.
Users can apply both companies' tools to view genomic evidence linked to disease mutations, reducing the time needed to examine a variant's pathogenicity.
The project will provide approved researchers with access to samples and deidentified data collected from volunteer patients with Duchenne muscular dystrophy.
The Voyage study is designed to enroll more than 150,000 people and will follow participants for at least seven years.
The companies will develop an assay to guide treatment with a type of radiopharmaceutical therapy in patients with these rare tumors.
The companies are collaborating to return actionable genetic information to all participants of the Project Baseline Health Study.
About a year ago, New York City-based Celmatix launched a division to discover therapeutics for women's health indications including reproductive disorders.
Russian CRISPR researcher moves along with plans to ultimately alter the genes of embryos of deaf couples, though awaits regulatory approval, Nature News reports.
University of California, San Francisco, researchers have uncovered a gene mutations that appears to make a father-son duo more efficient sleepers.
NPR reports a large health insurer has begun to cover some pharmacogenetic tests for psychiatric drugs.
In PLOS this week: genome-wide association study of non-syndromic orofacial cleft subtypes, epigenetic and transcriptomic analysis of pancreatic ductal adenocarcinoma, and more.